Frederick Financial Consultants LLC Invests $353,000 in United Therapeutics Co. (NASDAQ:UTHR)

Frederick Financial Consultants LLC purchased a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR) during the fourth quarter, Holdings Channel reports. The firm purchased 1,000 shares of the biotechnology company’s stock, valued at approximately $353,000.

Several other hedge funds have also recently added to or reduced their stakes in UTHR. Newbridge Financial Services Group Inc. purchased a new stake in United Therapeutics in the fourth quarter worth approximately $25,000. Millstone Evans Group LLC purchased a new position in United Therapeutics in the 4th quarter worth $67,000. MassMutual Private Wealth & Trust FSB lifted its stake in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 58 shares during the last quarter. Anchor Investment Management LLC boosted its position in United Therapeutics by 12.0% during the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 30 shares during the period. Finally, Jones Financial Companies Lllp grew its stake in shares of United Therapeutics by 678.9% during the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 258 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In related news, Director Raymond Dwek sold 3,000 shares of the stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $285.16, for a total transaction of $855,480.00. Following the transaction, the director now owns 1,750 shares in the company, valued at $499,030. This represents a 63.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction on Monday, January 27th. The stock was sold at an average price of $370.71, for a total value of $3,707,100.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $955,319.67. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 80,500 shares of company stock valued at $27,849,960 in the last quarter. 11.90% of the stock is owned by insiders.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $284.73 on Friday. United Therapeutics Co. has a 1-year low of $233.28 and a 1-year high of $417.82. The company has a market capitalization of $12.79 billion, a PE ratio of 12.50, a P/E/G ratio of 0.97 and a beta of 0.63. The firm’s 50-day moving average price is $317.98 and its 200-day moving average price is $349.16.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the firm posted $4.36 EPS. Equities analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

UTHR has been the subject of several analyst reports. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, UBS Group upped their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.